Disappointment as the supplier of an arthritis medication used by hundreds of New Zealanders is paused, due to overseas demand
Disappointment as the supplier of an arthritis medication used by hundreds of New Zealanders is paused, due to overseas demand
6 September 2021
Tocilizumab won't be available for about 400 New Zealanders for the next three months.
The medication's used overseas on hospitalised patients with moderate to severe Covid symptoms.
Medsafe hasn't approved that use in New Zealand.
Arthritis New Zealand chief executive Philip Kearney says it's a tough one.
He concedes it's having some benefits overseas, but it doesn't benefit people they look after in New Zealand.
© 2024 Newstalk ZB, NZCity